Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMPX NASDAQ:ICCC NASDAQ:PBYI NASDAQ:XFOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPXCompass Therapeutics$1.92+1.6%$4.26$1.61▼$6.88$345.77M0.795.44 million shs6.41 million shsICCCImmuCell$10.01+1.3%$7.46$4.52▼$10.25$90.59M0.522,185 shs25,897 shsPBYIPuma Biotechnology$7.05+0.9%$6.91$3.03▼$7.90$358.85M1.24365,798 shs175,078 shsXFORX4 Pharmaceuticals$4.04+7.2%$4.13$1.35▼$4.83$381.05M0.31443,571 shs254,695 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPXCompass Therapeutics+4.42%-4.06%-65.06%-70.42%-10.00%ICCCImmuCell-3.14%+18.18%+23.19%+48.13%+78.34%PBYIPuma Biotechnology+2.64%-2.51%-5.16%+2.95%+92.56%XFORX4 Pharmaceuticals+3.57%-10.87%-10.02%+21.61%+39.11%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPXCompass Therapeutics$1.92+1.6%$4.26$1.61▼$6.88$345.77M0.795.44 million shs6.41 million shsICCCImmuCell$10.01+1.3%$7.46$4.52▼$10.25$90.59M0.522,185 shs25,897 shsPBYIPuma Biotechnology$7.05+0.9%$6.91$3.03▼$7.90$358.85M1.24365,798 shs175,078 shsXFORX4 Pharmaceuticals$4.04+7.2%$4.13$1.35▼$4.83$381.05M0.31443,571 shs254,695 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPXCompass Therapeutics+4.42%-4.06%-65.06%-70.42%-10.00%ICCCImmuCell-3.14%+18.18%+23.19%+48.13%+78.34%PBYIPuma Biotechnology+2.64%-2.51%-5.16%+2.95%+92.56%XFORX4 Pharmaceuticals+3.57%-10.87%-10.02%+21.61%+39.11%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMPXCompass Therapeutics 2.86Moderate Buy$13.60606.49% UpsideICCCImmuCell 1.00SellN/AN/APBYIPuma Biotechnology 2.00HoldN/AN/AXFORX4 Pharmaceuticals 2.40Hold$8.50112.77% UpsideCurrent Analyst Ratings BreakdownLatest ICCC, XFOR, PBYI, and CMPX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/11/2026PBYIPuma Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)5/8/2026XFORX4 Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/28/2026CMPXCompass Therapeutics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform4/28/2026CMPXCompass Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$13.00 ➝ $7.004/28/2026CMPXCompass Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$10.004/27/2026CMPXCompass Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.004/27/2026CMPXCompass Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.004/24/2026XFORX4 Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026PBYIPuma Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)4/20/2026CMPXCompass Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/6/2026ICCCImmuCell Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D-)(Data available from 5/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMPXCompass Therapeutics$850K407.85N/AN/A$1.04 per share1.85ICCCImmuCell$27.64M3.20$0.18 per share52.91$3.22 per share3.04PBYIPuma Biotechnology$228.40M1.57$0.86 per share8.16$2.52 per share2.80XFORX4 Pharmaceuticals$35.11M10.73N/AN/A$1.79 per share2.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMPXCompass Therapeutics-$66.49M-$0.41N/AN/AN/AN/A-39.75%-35.29%N/AICCCImmuCell-$1.04M-$0.06N/AN/AN/A-1.82%-1.88%-1.22%N/APBYIPuma Biotechnology$31.11M$0.4814.6737.08N/A10.69%20.30%12.05%8/6/2026 (Estimated)XFORX4 Pharmaceuticals-$79.20M-$4.54N/AN/AN/A-1,106.30%-94.90%-48.09%8/6/2026 (Estimated)Latest ICCC, XFOR, PBYI, and CMPX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026ICCCImmuCell$0.05$0.21+$0.16$0.21$5.40 million$10.36 million5/7/2026Q1 2026PBYIPuma Biotechnology-$0.13-$0.04+$0.09-$0.07$42.00 million$44.81 million5/6/2026Q1 2026XFORX4 Pharmaceuticals-$0.20-$0.16+$0.04-$0.16$3.20 million$2.71 million5/5/2026Q1 2026CMPXCompass Therapeutics-$0.10-$0.10N/A-$0.10($0.82) millionN/A3/17/2026Q4 2025XFORX4 Pharmaceuticals-$0.36-$0.22+$0.14$1.00$1.68 million$2.57 million3/5/2026Q4 2025CMPXCompass Therapeutics-$0.10-$0.09+$0.01-$0.09($0.90) millionN/A2/26/2026Q4 2025PBYIPuma Biotechnology$0.24$0.26+$0.02$0.26$68.60 million$75.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCMPXCompass TherapeuticsN/AN/AN/AN/AN/AICCCImmuCellN/AN/AN/AN/AN/APBYIPuma BiotechnologyN/AN/AN/AN/AN/AXFORX4 PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMPXCompass TherapeuticsN/A19.0419.04ICCCImmuCell0.244.822.60PBYIPuma BiotechnologyN/A2.382.24XFORX4 Pharmaceuticals0.4510.189.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMPXCompass Therapeutics68.43%ICCCImmuCell13.47%PBYIPuma Biotechnology61.29%XFORX4 Pharmaceuticals72.03%Insider OwnershipCompanyInsider OwnershipCMPXCompass Therapeutics18.70%ICCCImmuCell5.70%PBYIPuma Biotechnology22.20%XFORX4 Pharmaceuticals1.13%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMPXCompass Therapeutics20180.09 million146.41 millionNot OptionableICCCImmuCell709.05 million8.53 millionNot OptionablePBYIPuma Biotechnology20050.90 million39.60 millionOptionableXFORX4 Pharmaceuticals8094.32 million93.25 millionNo DataICCC, XFOR, PBYI, and CMPX HeadlinesRecent News About These CompaniesHow The X4 Pharmaceuticals (XFOR) Story Is Shifting With Mavorixafor And New EU ProgressMay 21 at 5:48 AM | finance.yahoo.comBears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' NowMay 20 at 10:55 AM | zacks.comX4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should KnowMay 18 at 1:01 PM | zacks.comHere is Why X4 Pharmaceuticals (XFOR) is Among the Unrivaled Penny Stocks to Buy NowMay 15, 2026 | finance.yahoo.comHere is Why X4 Pharmaceuticals (XFOR) is Among the Unrivaled Penny Stocks to Buy NowMay 14, 2026 | insidermonkey.comGuggenheim Sticks to Their Buy Rating for X4 Pharmaceuticals (XFOR)May 11, 2026 | theglobeandmail.comX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Rating of "Hold" by BrokeragesMay 11, 2026 | marketbeat.comQ2 EPS Forecast for X4 Pharmaceuticals Raised by AnalystMay 11, 2026 | marketbeat.comResearch Analysts Issue Forecasts for XFOR FY2029 EarningsMay 8, 2026 | marketbeat.comX4 Pharmaceuticals (NASDAQ:XFOR) Issues Earnings ResultsMay 6, 2026 | marketbeat.comX4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue EstimatesMay 6, 2026 | zacks.comX4 Pharmaceuticals Reports Positive Updates on 4WARD Phase 3 Trial and European Commission Approval for XOLREMDI®May 6, 2026 | quiverquant.comQX4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 6, 2026 | globenewswire.comX4 Pharmaceuticals (XFOR) to Release Earnings on ThursdayApril 30, 2026 | marketbeat.comX4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European UnionApril 29, 2026 | globenewswire.comOne X4 Pharmaceuticals Insider Raised Their Stake In The Previous YearApril 9, 2026 | finance.yahoo.comX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 1, 2026 | globenewswire.comX4 Pharmaceuticals (XFOR) price target increased by 25.00% to 11.90March 27, 2026 | msn.comX4 Jumps on Q4 FiguresMarch 17, 2026 | baystreet.caX4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue EstimatesMarch 17, 2026 | zacks.comX4 Pharmaceuticals Reports Positive EMA Opinion on Mavorixafor and Updates on 4WARD Phase 3 Trial Enrollment ProgressMarch 17, 2026 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026AMD’s Breakout Isn’t the Story—This Catalyst IsBy Thomas Hughes | April 24, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026Sell in May and Go Away—Starting With These 3 StocksBy Bridget Bennett | May 12, 2026ICCC, XFOR, PBYI, and CMPX Company DescriptionsCompass Therapeutics NASDAQ:CMPX$1.92 +0.03 (+1.59%) Closing price 04:00 PM EasternExtended Trading$1.92 0.00 (-0.26%) As of 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.ImmuCell NASDAQ:ICCC$10.01 +0.13 (+1.32%) Closing price 04:00 PM EasternExtended Trading$9.95 -0.06 (-0.60%) As of 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.Puma Biotechnology NASDAQ:PBYI$7.05 +0.06 (+0.86%) Closing price 04:00 PM EasternExtended Trading$7.05 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.X4 Pharmaceuticals NASDAQ:XFOR$4.04 +0.27 (+7.16%) Closing price 04:00 PM EasternExtended Trading$4.04 0.00 (0.00%) As of 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Target Shows Strengths, But Analysts Want to See More Freight Boom: The Hormuz Blockade Payday TJX Companies Fires on All Cylinders With 9% Revenue Growth Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
